Agence Nacional de Vigilância Sanitária (Anvisa) Photo: Marcelo Camargo/Agência Brasil The Agence Nacional de Vigilância Sanitária (Anvisa) approved on Wednesday (30) the registration of the drug Farmanguinhos Arpraziquantel, indicated for the treatment of schistosomosis caused by the parasite Schistosome mansoni or Schistosome haematobium in children from 3 months to 6 years.The resolution was published in the Official Journal of the Union.In a…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Agence Nacional de Vigilância Sanitária (Anvisa) Photo: Marcelo Camargo/Agência Brasil The Agence Nacional de Vigilância Sanitária (Anvisa) approved on Wednesday (30) the registration of the drug Farmanguinhos Arpraziquantel, indicated for the treatment of schistosomosis caused by the parasite Schistosome mansoni or Schistosome haematobium in children from 3 months to 6 years.The resolution was published in the Official Journal of the Union.In a…